Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Carfilzomib
Drug ID BADD_D00367
Description Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392]
Indications and Usage Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.[L39392]
Marketing Status approved; investigational
ATC Code L01XG02
DrugBank ID DB08889
KEGG ID D08880
MeSH ID C524865
PubChem ID 11556711
NDC Product Code 76055-0035; 76075-103; 76075-101; 63552-009; 67262-0010; 42385-731; 76075-102; 63552-035; 54893-0037; 52076-6251; 55111-985; 11722-059
Synonyms carfilzomib | PR-171 | PR171 | Kyprolis
Chemical Information
Molecular Formula C40H57N5O7
CAS Registry Number 868540-17-4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypotonia15.05.04.008; Available
Immune system disorder10.02.01.0010.000604%Not Available
Impaired gastric emptying07.02.02.0040.000112%
Infection11.01.08.002--Not Available
Influenza like illness08.01.03.0100.001802%
Injection site erythema23.03.06.015;; Available
Injection site extravasation12.07.03.002; Available
Injection site irritation12.07.03.027; Available
Intestinal perforation07.04.06.0020.000112%Not Available
Joint swelling15.01.02.0040.002205%Not Available
Left ventricular failure02.05.02.0010.000224%Not Available
Leukopenia01.02.02.001--Not Available
Lung disorder22.02.07.0010.001455%Not Available
Lung infiltration22.01.02.0040.000470%Not Available
Lymphopenia01.02.02.0020.000224%Not Available
Malignant hypertension24.08.01.0020.000224%Not Available
Mass08.03.05.0030.000739%Not Available
Memory impairment19.20.01.003;
Metastases to spine16.22.02.007; Available
Microangiopathic haemolytic anaemia24.03.02.019; Available
Mitral valve incompetence02.07.01.0020.000224%Not Available
Monoplegia17.01.04.0030.000112%Not Available
Mucosal inflammation08.01.06.002--Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005;
Musculoskeletal pain15.03.04.0070.001668%
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 12 Pages